Dr. Helen Heslop elected to the National Academy of Medicine
Election to the National Academy of Medicine recognizes outstanding professional achievement and commitment to service.
Read More
Search Results for: Heslop
CAR T cell therapy for T cell lymphoma shows promise in phase I trial
A first-in-human phase I clinical trial of patients with relapsed or refractory T cell lymphoma found early signals of anti-tumor efficacy and safety.
Read More
Promising approach to mitigate complications of leukemia treatment
The findings support further assessing this approach to treat aggressive blood cancers and ultimately improve outcomes in patients.
Read More
Fighting cancer with rejection-resistant, ‘off-the-shelf’ therapeutic T cells
Baylor College of Medicine researchers extend the life and effectiveness of off-the-shelf, cancer-fighting immune T cells.
Read More
CAR T cell therapy makes strides in tackling Hodgkin lymphoma
CAR-T cell therapy has been used to treat Hodgkin lymphoma with remarkable success for the first time in an early phase clinical trial.
Read More
New insights into the mediators of patient recovery after CAR T cell immunotherapy
Clinical trial of novel personalized CAR T cell immunotherapy provides clues into what mediated exceptional patient recovery.
Read More
Baylor College of Medicine Women in Science
From the Labs celebrates Baylor College of Medicine’s Women of Science.
Read More
Fighting back lymphoma resistance to treatment
T cell therapies have demonstrated encouraging results and benefits in patients with lymphoma resistant to chemotherapy, but, despite these advances, a large number of patients
Read More
“Off-the-shelf” cells are safe and effective to treat viral infections
A bone marrow transplant can be a life-saving treatment for patients with certain cancers and other serious illnesses that have not responded to conventional chemotherapies.
Read More
Targeting B-cell malignancies with κ-specific T cells can lead to complete clinical responses
Treating cancer with the patient’s own immune cells has been successful. In particular, treating B cell malignancies with the patients’ own immune T cells modified
Read More